Navigation Links
Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
Date:10/8/2008

PRINCETON, N.J., Oct. 8 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Natixis Bleichroeder Hidden Gems Conference being held from October 13-14, 2008 at the Waldorf Astoria in New York City. Michelle Berrey, Pharmasset's Chief Medical Officer, will provide an overview of the company on Monday, October 13, 2008, at 11:30 AM (ET).

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Richard E.T. Smith

Vice President of Investor Relations

richard.smith@pharmasset.com

Office: +1 (609) 613-4181


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
2. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
3. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
4. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
5. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
6. Pharmasset Joins Russell 3000 Index
7. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
8. Pharmasset Selected to Join the NASDAQ Biotechnology Index
9. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
10. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
11. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... two-dimensional representations of a complex biological network, a depiction of a system of ... mess,” said Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality ... Several trends in analytical testing are being attributed to new regulatory requirements for ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):